NCT06148272View on ClinicalTrials.gov

A Study of LY3971297 in Healthy Participants

PHASE1RecruitingINTERVENTIONAL
Enrollment

225

Participants

Timeline

Start Date

December 7, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
HealthyObesityHypertension
Interventions
DRUG

LY3971297

Administered SC

DRUG

Placebo

Administered SC

DRUG

LY3971297 IV

Administered IV

Trial Locations (6)

78209

RECRUITING

ICON Early Phase Services, San Antonio

92801

RECRUITING

CenExel ACT, Anaheim

138623

RECRUITING

Lilly Centre for Clinical Pharmacology, Singapore

812-0025

RECRUITING

Hakata Clinic, Fukuoka

192-0071

RECRUITING

P-One Clinic, Hachiōji

160-0004

RECRUITING

Clinical Research Hospital Tokyo, Shinjuku-ku

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT06148272 - A Study of LY3971297 in Healthy Participants | Biotech Hunter | Biotech Hunter